JPWO2020241853A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020241853A5
JPWO2020241853A5 JP2021522912A JP2021522912A JPWO2020241853A5 JP WO2020241853 A5 JPWO2020241853 A5 JP WO2020241853A5 JP 2021522912 A JP2021522912 A JP 2021522912A JP 2021522912 A JP2021522912 A JP 2021522912A JP WO2020241853 A5 JPWO2020241853 A5 JP WO2020241853A5
Authority
JP
Japan
Prior art keywords
methyl
benzo
dimethyl
ethyl
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522912A
Other languages
English (en)
Japanese (ja)
Other versions
JP7524899B2 (ja
JPWO2020241853A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/021426 external-priority patent/WO2020241853A1/ja
Publication of JPWO2020241853A1 publication Critical patent/JPWO2020241853A1/ja
Publication of JPWO2020241853A5 publication Critical patent/JPWO2020241853A5/ja
Application granted granted Critical
Publication of JP7524899B2 publication Critical patent/JP7524899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522912A 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体 Active JP7524899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019102529 2019-05-31
JP2019102529 2019-05-31
PCT/JP2020/021426 WO2020241853A1 (ja) 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体

Publications (3)

Publication Number Publication Date
JPWO2020241853A1 JPWO2020241853A1 (https=) 2020-12-03
JPWO2020241853A5 true JPWO2020241853A5 (https=) 2023-05-12
JP7524899B2 JP7524899B2 (ja) 2024-07-30

Family

ID=73553193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522912A Active JP7524899B2 (ja) 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体

Country Status (11)

Country Link
US (1) US12559504B2 (https=)
EP (1) EP3978073B1 (https=)
JP (1) JP7524899B2 (https=)
KR (1) KR20220016124A (https=)
CN (1) CN114174289B (https=)
AU (1) AU2020283361B2 (https=)
BR (1) BR112021023927A2 (https=)
CA (1) CA3142295A1 (https=)
ES (1) ES3047102T3 (https=)
MX (1) MX2021014680A (https=)
WO (1) WO2020241853A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065501T2 (hu) 2018-08-20 2024-05-28 Janssen Pharmaceutica Nv A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok
CN113024399B (zh) * 2021-03-11 2022-09-09 华东理工大学 药物中间体化合物及其制备方法、应用
KR20230110001A (ko) * 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
JP7605446B2 (ja) 2022-04-28 2024-12-24 第一三共株式会社 ベンゾトリアゾール化合物
US20250296939A1 (en) * 2022-04-28 2025-09-25 Kyoto Pharmaceutical Industries, Ltd. Benzothiophene compound
WO2024262491A1 (ja) * 2023-06-19 2024-12-26 中外製薬株式会社 Nrf2活性化作用を有する含窒素複素環化合物の結晶
WO2025192605A1 (ja) * 2024-03-12 2025-09-18 株式会社GALTS Pharma 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102301867B1 (ko) 2013-12-18 2021-09-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
RU2703456C2 (ru) 2014-07-25 2019-10-17 Тайсо Фармасьютикал Ко., Лтд. Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом
EP3766878B1 (en) 2015-06-15 2022-03-16 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
CA2988373A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
SI3782996T1 (sl) 2015-06-15 2024-06-28 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulatorji
WO2017060855A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
CN108779108A (zh) 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
EP3551621A1 (en) 2016-12-12 2019-10-16 GlaxoSmithKline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
JP2020502136A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2レギュレーターとしてのビスアリールアミド
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
US11059816B2 (en) 2016-12-15 2021-07-13 Glaxosmithkline Intellectual Property Development Limited Ether linked triazoles as NRF2 activators
CA3044773A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 activators
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
WO2019116231A1 (en) * 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
US20210177861A1 (en) 2017-12-11 2021-06-17 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
JP2021524469A (ja) 2018-05-23 2021-09-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのインダン
HUE065501T2 (hu) 2018-08-20 2024-05-28 Janssen Pharmaceutica Nv A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok
NZ776102A (en) 2018-12-05 2024-12-20 Scohia Pharma Inc Macrocyclic compound and use thereof
JP7602469B2 (ja) * 2019-02-15 2024-12-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン
CN114080389B (zh) 2019-07-03 2024-08-30 千寿制药株式会社 Nrf2活性化化合物
EP4110776A1 (en) 2020-02-28 2023-01-04 Les Laboratoires Servier New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Similar Documents

Publication Publication Date Title
JPWO2020241853A5 (https=)
ES2207983T3 (es) Derivados de epotilona y su uso como agentes antitumorales.
JP6093770B2 (ja) 癌の治療のためのmdm2阻害剤としての複素環化合物
AU2019342102C1 (en) Compounds for treating certain leukemias
IL285399B2 (en) Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
CN116528869B (zh) 氨基杂芳基激酶抑制剂
CA2972952C (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
JP2016121177A (ja) 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物
KR20240152322A (ko) Cdk4/6 키나제의 억제제
CN118475558A (zh) 一种磺酰脲类化合物
JP2025534444A (ja) ホスホルアミダート化合物及びその用途
ES2341075B1 (es) Nitratos de isosorbida.
CA2916338C (en) 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
EP2149577B1 (en) New stereospecific method for the preparation of dioxa-bicyclooctane compounds
Nakayama et al. Cyclization reactions of hydrazones induced by isocyanates. Syntheses of 1, 3, 4-thiadiazoline and 1, 2, 4-triazoline derivatives
Cumming et al. Synthesis of a simplified triazole analogue of pateamine A
JP2022509147A (ja) 1,2,3,4-テトラヒドロキノキサリン誘導体、その製造方法および使用
ES2331296B1 (es) Derivados de 1-azaespiro (3.5)nonan-2-ona-5,7-carbolactona y 5.7-protegido-1-azaespiro (3.5)nonan-2-ona y su uso como productos intermedios en la sintesis de ttx.
US20250304601A1 (en) Processes for Preparing KRAS Inhibitors
WO2013076590A1 (en) Benzothiazine compounds as h3 receptor ligands
HK40092567A (zh) 氨基杂芳基激酶抑制剂
TW202543630A (zh) 作為tead抑制劑的螺環化合物
KR20230112683A (ko) 항콜린제
EA050841B1 (ru) Гетероциклические производные для лечения расстройств, опосредованных trpm3
EA040984B1 (ru) Ингибиторы magl на основе пиразола